STOCK TITAN

Balyasny Asset Management (NERV) discloses 9.99% Minerva Neurosciences ownership via shares and warrants

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Balyasny Asset Management L.P. and affiliated entities report beneficial ownership of common stock of Minerva Neurosciences, Inc. The group may be deemed to beneficially own 4,654,212 shares, including 4,257,000 shares held by Atlas Private Holdings (Cayman) Ltd. and 397,212 shares issuable upon exercise of warrants.

This position represents approximately 9.99% of the outstanding shares, based on 46,588,709 shares outstanding as of April 30, 2026. The 13,500 warrants are subject to a Beneficial Ownership Limitation that prevents exercises which would increase ownership above 9.99%. Each reporting person has sole voting and dispositive power over 4,654,212 shares, with no shared power reported.

Positive

  • None.

Negative

  • None.
Beneficially owned shares 4,654,212 shares Total shares the reporting persons may be deemed to beneficially own
Directly held and issuable shares 4,257,000 shares Shares of common stock held by APHC, including warrant shares
Warrant underlying shares 397,212 shares Shares issuable upon exercise of 13,500 warrants
Warrants 13,500 Warrants Warrants subject to the Beneficial Ownership Limitation
Ownership percentage 9.99% Approximate percentage of Minerva’s common stock class beneficially owned
Shares outstanding 46,588,709 Shares Minerva common shares outstanding as of April 30, 2026
Sole voting power 4,654,212 shares Shares over which each reporting person has sole power to vote
Sole dispositive power 4,654,212 shares Shares over which each reporting person has sole power to dispose
Beneficial Ownership Limitation regulatory
"The Warrants are subject to a blocker which prevents the holder from exercising the Warrants to the extent that, upon such exercise, the holder would beneficially own in excess of 9.99% of the Shares outstanding as a result of the exercise (the "Beneficial Ownership Limitation")."
A beneficial ownership limitation is a rule that caps the percentage of a company’s shares an investor can be treated as owning or controlling for voting, regulatory or tax purposes. It matters to investors because it can restrict how many shares a person or group can buy or vote, affect takeover chances, and influence share liquidity and value — like a speed limit that prevents any single driver from taking over the whole road.
beneficial owner regulatory
"Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
Sole Voting Power financial
"Each of the Reporting Persons has the sole power to vote or to direct the vote of 4654212 shares."
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Each of the Reporting Persons has the sole power to dispose or to direct the disposition of 4654212 shares."
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
Schedule 13G regulatory
"Each of the Reporting Persons may be deemed to be the beneficial owner of approximately 9.99% of the Shares"
A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

How much of Minerva Neurosciences (NERV) does Balyasny Asset Management beneficially own?

Balyasny Asset Management and related entities may be deemed to beneficially own 4,654,212 shares of Minerva Neurosciences common stock, including 4,257,000 shares held by APHC and 397,212 shares issuable upon exercise of warrants.

What percentage of Minerva Neurosciences (NERV) is held by the Balyasny reporting group?

The reporting group states beneficial ownership of approximately 9.99% of Minerva’s common stock, based on 46,588,709 shares outstanding as of April 30, 2026, as disclosed in Minerva’s Form 10-Q.

Who directly holds the Minerva Neurosciences (NERV) shares managed by Balyasny?

The 4,257,000 common shares (including shares underlying warrants) are held directly by Atlas Private Holdings (Cayman) Ltd. (APHC), an investment management client of Balyasny Asset Management L.P., which may be deemed to exercise voting and investment power.

What voting and dispositive power does Balyasny report over Minerva Neurosciences (NERV) stock?

Each reporting person reports sole voting power over 4,654,212 shares and sole dispositive power over 4,654,212 shares of Minerva Neurosciences common stock, with no shared voting or dispositive power disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





603380205

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BALYASNY ASSET MANAGEMENT L.P.
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
BAM GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Balyasny Asset Management Holdings LP
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Dames GP LLC
Signature:/s/ Scott Schroeder
Name/Title:Scott Schroeder / Authorized Signatory
Date:08/14/2026
Dmitry Balyasny
Signature:/s/ Dmitry Balyasny
Name/Title:Dmitry Balyasny / Self
Date:08/14/2026